Skip to main navigation Skip to search Skip to main content

Recombinant tissue plasminogen activator may reduce frequency of central venous access device infection in hemophilia patients undergoing immune tolerance therapy

  • Amy L. Dunn
  • , Thomas C. Abshire

Research output: Contribution to journal › Article › peer-review

Abstract

Many patients with hemophilia, particularly those with inhibitory antibodies, utilize central venous access devices (CVADs) to facilitate frequent infusions. Infection of these devices is a common complication of factor replacement therapy. This communication reports our center's experience with CVAD infection in three patients with severe hemophilia A undergoing immune tolerance therapy (ITT) in whom intermittent infusions of recombinant tissue plasminogen activator (rTPA, Cathflo™ Activase®) were utilized. In this small experience, patients experienced a decreased frequency of gram-positive infections when receiving routine rTPA treatments. Larger randomized trial should be performed in this patient population at high risk of CVAD infection.

Original languageEnglish
Pages (from-to)627-629
Number of pages3
JournalPediatric Blood and Cancer
Volume50
Issue number3
DOIs
StatePublished - Mar 2008

Keywords

  • Central venous access device
  • Hemophilia
  • Infection
  • Tissue plasminogen activator

Fingerprint

Dive into the research topics of 'Recombinant tissue plasminogen activator may reduce frequency of central venous access device infection in hemophilia patients undergoing immune tolerance therapy'. Together they form a unique fingerprint.

Cite this